Glucose 6 phosphate dehydrogenase deficiency

Glucose-6-phosphate dehydrogenase deficiency, the most common enzyme deficiency worldwide, causes a spectrum of disease including neonatal hyperbilirubinemia, acute hemolysis, and chronic hemolysis. Persons with this condition also may be asymptomatic. This X-linked inherited disorder most commonly affects persons of African, Asian, Mediterranean, or Middle-Eastern descent. Approximately 400 million people are affected worldwide. Homozygotes and heterozygotes can be symptomatic, although the disease typically is more severe in persons who are homozygous for the deficiency. The conversion of nicotinamide adenine dinucleotide phosphate to its reduced form in erythrocytes is the basis of diagnostic testing for the deficiency. This usually is done by fluorescent spot test. Different gene mutations cause different levels of enzyme deficiency, with classes assigned to various degrees of deficiency and disease manifestation. Because acute hemolysis is caused by exposure to an oxidative stressor in the form of an infection, oxidative drug, or fava beans, treatment is geared toward avoidance of these and other stressors. Acute hemolysis is self-limited, but in rare instances it can be severe enough to warrant a blood transfusion. Neonatal hyperbilirubinemia may require treatment with phototherapy or exchange transfusion to prevent kernicterus. The variant that causes chronic hemolysis is uncommon because it is related to sporadic gene mutation rather than the more common inherited gene mutation.

**********

Glucose-6-phosphate dehydrogenase (G6PD) deficiency increases the vulnerability of erythrocytes to oxidative stress. Clinical presentations include acute hemolytic anemia, chronic hemolytic anemia, neonatal hyperbilirubinemia, and an absence of clinical symptoms. The disease is rarely fatal.

Epidemiology

G6PD deficiency occurs with increased frequency throughout Africa, Asia, the Mediterranean, and the Middle East. In the United States, black males are most commonly affected, with a prevalence of approximately 10 percent. Prevalence of the deficiency is correlated with the geographic distribution of malaria, which has led to the theory that carriers of G6PD deficiency may incur partial protection against malarial infection. (1-3) Cases of sporadic gene mutation occur in all populations.

Pathophysiology

G6PD catalyzes nicotinamide adenine dinucleotide phosphate (NADP) to its reduced form, NADPH, in the pentose phosphate pathway (Figure 1 (4)). NADPH protects cells from oxidative damage. Because erythrocytes do not generate NADPH in any other way, (3) they are more susceptible than other cells to destruction from oxidative stress. The level of G6PD activity in affected erythrocytes generally is lower than in other cells. (5) Normal red blood cells that are not under oxidative stress generally exhibit G6PD activity at approximately 2 percent of total capacity. (1) Even with enzyme activity that is substantially reduced, there may be few or no clinical symptoms. A total deficiency of G6PD is incompatible with life. (6) The G6PD-deficient variants are grouped into different classes corresponding with disease severity (Table 1 (1,7)).

[FIGURE 1 OMITTED]

Genetics

The gene mutations affecting encoding of G6PD are found on the distal long arm of the X chromosome. More than 400 mutations have been identified, most being missense mutations. (6) Most of the variants occur sporadically, although the G6PD Mediterranean and the G6PD A- variants occur with increased frequency in certain populations (Table 2 (3,6,7)).

Diagnosis

The diagnosis of G6PD deficiency is made by a quantitative spectrophotometric analysis or, more commonly, by a rapid fluorescent spot test detecting the generation of NADPH from NADP. (7) The test is positive if the blood spot fails to fluoresce under ultraviolet light. (8) In field research, where quick screening of a large number of patients is needed, other tests have been used; however, they require definitive testing to confirm an abnormal result. (9,10) Tests based on polymerase chain reaction detect specific mutations and are used for population screening, family studies, or prenatal diagnosis. (6)

In patients with acute hemolysis, testing for G6PD deficiency may be falsely negative because older erythrocytes with a higher enzyme deficiency have been hemolyzed. Young erythrocytes and reticulocytes have normal or near-normal enzyme activity. female heterozygotes may be hard to diagnose because of X-chromosome mosaicism leading to a partial deficiency that will not be detected reliably with screening tests. (7,11,12)

G6PD deficiency is one of a group of congenital hemolytic anemias, and its diagnosis should be considered in children with a family history of jaundice, anemia, splenomegaly, or cholelithiasis, especially in those of Mediterranean or African ancestry. (13)

Testing should be considered in children and adults (especially males of African, Mediterranean, or Asian descent) with an acute hemolytic reaction caused by infection, exposure to a known oxidative drug, or ingestion of fava beans.

Although rare, G6PD deficiency should be considered as a cause of any chronic nonspherocytic hemolytic anemia across all population groups.

Newborn screening for G6PD deficiency is not performed routinely in the United States, although it is done in countries with high disease prevalence. The World Health Organization recommends screening all newborns in populations with a prevalence of 3 to 5 percent or more in males. (3)

Neonatal Hyperbilirubinemia

The prevalence of neonatal hyperbilirubinemia is twice that of the general population (14) in males who carry the defective gene and in homozygous females. It rarely occurs in heterozygous females. (15,16)

The mechanism by which G6PD deficiency causes neonatal hyperbilirubinemia is not completely understood. Although hemolysis may be observed in neonates who have G6PD deficiency and are jaundiced, (17) other mechanisms appear to play a more important role in the development of hyperbilirubinemia. (6,18,19) Hyperbilirubinemia is likely secondary to impairment of bilirubin conjugation and clearance by the liver leading to indirect hyperbilirubinemia. (6,20) Infants with G6PD deficiency and a mutation of uridine diphosphoglucuronate glucuronosyltransferase-1 gene promoter (UDPGT-1) are particularly susceptible to hyperbilirubinemia secondary to decreased liver clearance of bilirubin. (21) UDPGT-1 is the enzyme affected in Gilbert disease.

G6PD deficiency should be considered in neonates who develop hyperbilirubinemia within the first 24 hours of life, a history of jaundice in a sibling, bilirubin levels greater than the 95th percentile, and in Asian males. (22,23)

G6PD deficiency can lead to an increased risk and earlier onset of hyperbilirubinemia, (24,25) which may require phototherapy or exchange transfusion. (6,25) In certain populations, hyperbilirubinemia secondary to G6PD deficiency results in an increased rate of kernicterus and death, (26,27) whereas in other populations this has not been observed. (18) This may reflect genetic mutations specific to different ethnic groups. (18,19)

Acute Hemolysis

Acute hemolysis is caused by infection, ingestion of fava beans, or exposure to an oxidative drug. (3) Medications that should be avoided in patients with G6PD deficiency are listed in Table 3, (6) and drugs that can be used safely in these patients are listed in Table 4. (6) Hemolysis occurs after exposure to the stressor but does not continue despite continued infection or ingestion. This is thought to be a result of older erythrocytes having the greatest enzyme deficiency and undergoing hemolysis first. Once the population of deficient erythrocytes has been hemolyzed, younger erythrocytes and reticulocytes that typically have higher levels of enzyme activity are able to sustain the oxidative damage without hemolysis. (7) Clinically, acute hemolysis can cause back or abdominal pain and jaundice secondary to a rise in unconjugated bilirubin (Table 5 (21)). jaundice, in the setting of normal liver function, typically does not occur until greater than 50 percent of the erythrocytes have been hemolyzed. (21)

Drugs that cause hemolysis in G6PD-deficient persons inf lict oxidative damage to erythrocytes leading to erythrocyte destruction. Hemolysis typically occurs 24 to 72 hours after ingestion, with resolution within four to seven days. (21) Oxidative drugs ingested by a woman who is breastfeeding may be transmitted in breast milk and can cause acute hemolysis in a G6PD-deficient child. (16,28)

Although persons who experience hemolysis after the ingestion of fava beans can be presumed to have G6PD deficiency, not all of them will exhibit hemolysis. (6,7) favism is most common in persons with G6PD class II variants, but rarely it can occur in patients with the G6PD A--variant. (5) fava beans (Table 6) are presumed to cause oxidative damage by an unknown component, possibly vicine, convicine, or isouramil. (6,7)

Infection is the most common cause of acute hemolysis in G6PD-deficient persons, (6) although the exact mechanism by which this occurs is unknown. Leukocytes may release oxidants during phagocytosis that cause oxidative stress to the erythrocytes; however, this explanation alone would not account for the variety of infections associated with hemolysis in G6PD-deficient persons. The most common infectious agents causing hemolysis include Salmonella, Escherichia coli, beta-hemolytic streptococci, rickettsial infections, viral hepatitis, and influenza A.

A peripheral smear taken during an acute hemolytic reaction in a G6PD-deficient person may demonstrate Heinz bodies, although this rarely is seen in clinical practice. (7)

Chronic Hemolysis

In chronic nonspherocytic hemolytic anemia, which usually is caused by a sporadic gene mutation, hemolysis occurs during normal erythrocyte metabolism. (5,6) The severity of the hemolysis varies, causing mild hemolysis to transfusion-dependent anemia. Exposure to oxidative stress can cause acute hemolysis in these persons.

Other clinical considerations

G6PD-deficient persons are predisposed to the development of sepsis and complications related to sepsis after a severe injury. (29) Although research has failed to consistently show a clinically significant risk to patients receiving G6PD-deficient donor blood, blood banks generally do not accept G6PD-deficient blood donors. (30)

Treatment

The main treatment for G6PD deficiency is avoidance of oxidative stressors. Rarely, anemia may be severe enough to warrant a blood transfusion. Splenectomy generally is not recommended. Folic acid and iron potentially are useful in hemolysis, although G6PD deficiency usually is asymptomatic and the associated hemolysis usually is short-lived. Antioxidants such as vitamin E and selenium have no proven benefit for the treatment of G6PD deficiency. (6,31) research is being done to identify medications that may inhibit oxidative-induced hemolysis of G6PD-deficient red blood cells. (32)

The author thanks Benjamin S. Frank, M.D., Ph.D., for reviewing the manuscript.

Author disclosure: Nothing to disclose.

REFERENCES

(1.) Ruwende C, Hill A. Glucose-6-phosphate dehydrogenase deficiency and malaria. J Mol Med 1998;76:581-8.

(2.) Mockenhaupt FP, Mandelkow J, Till H, Ehrhardt S, Eggelte TA, Bienzle U. Reduced prevalence of Plasmodium falciparum infection and of concomitant anaemia in pregnant women with heterozygous G6PD deficiency. Trop Med Int Health 2003;8:118-24.

(3.) WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ 1989;67:601-11.

(4.) Glucose 6 phosphate dehydrogenase deficiency. Accessed July 20, 2005, at: http://www.malariasite. com/malaria/g6pd.htm.

(5.) Mason PJ. New insights into G6PD deficiency. Br J Haematol 1996;94:585-91.

(6.) Beutler e. G6PD deficiency. Blood 1994;84:3613-36.

(7.) Gregg XT, Prchal JT. Red cell enzymopathies. In: Hoffman R, ed. Hematology: basic principles and practice. 4th ed. Philadelphia: Churchill Livingstone, 2000:657-60.

(8.) Glucose-6-phosphate dehyrdogenase deficiency. Accessed online July 20, 2005, at: http://www.answers. com/glucose-6-phosphate-dehydrogenase-deficiency.

(9.) Jalloh A, Tantular IS, Pusarawati S, Kawilarang AP, Kerong H, Lin K, et al. Rapid epidemiologic assessment of glucose-6-phosphate dehydrogenase deficiency in malaria-endemic areas in Southeast Asia using a novel diagnostic kit. Trop Med Int Health 2004;9:615-23.

(10.) Iwai K, Matsuoka H, Kawamoto F, Arai M, Yoshida S, Hirai M, et al. A rapid single-step screening method for glucose-6-phosphate dehydrogenase deficiency in field applications. Japanese Journal of Tropical Medicine and Hygiene 2003;31:93-7.

(11.) Ainoon O, Alawiyah A, Yu YH, Cheong SK, Hamidah NH, Boo NY, et al. Semiquantitative screening test for G6PD deficiency detects severe deficiency but misses a substantial proportion of partially-deficient females. Southeast Asian J Trop Med Public Health 2003;34:405-14.

(12.) Reclos GJ, Hatzidakis CJ, Schulpis KH. Glucose-6-phosphate dehydrogenase deficiency neonatal screening: preliminary evidence that a high percentage of partially deficient female neonates are missed during routine screening. J Med Screen 2000;7:46-51.

(13.) Hermiston ML, Mentzer WC. A practical approach to the evaluation of the anemic child. Pediatr Clin North Am 2002;49:877-91.

(14.) Glucose-6-phosphate dehydrogenase; G6PD. Accessed online July 20, 2005, at: http://www3.ncbi.nlm.nih. gov/entrez/dispomim.cgi?id=305900.

(15.) Kaplan M, Hammerman C, Vreman HJ, Stevenson DK, Beutler e. Acute hemolysis and severe neonatal hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient heterozygotes. J Pediatr 2001;139:137-40.

(16.) Corchia C, Balata A, Meloni GF, Meloni T. Favism in a female newborn infant whose mother ingested fava beans before delivery. J Pediatr 1995;127:807-8.

(17.) Bizzarro MJ, Colson E, Ehrenkranz RA. Differential diagnosis and management of anemia in the newborn. Pediatr Clin North Am 2004;51:1087-107,xi.

(18.) Kaplan M, Vreman HJ, Hammerman C, Leiter C, Abramov A, Stevenson DK. Contribution of haemolysis to jaundice in Sephardic Jewish glucose-6-phosphate dehydrogenase deficient neonates. Br J Haematol 1996;93:822-7.

(19.) Seidman DS, Shiloh M, Stevenson DK, Vreman HJ, Gale R. Role of hemolysis in neonatal jaundice associated with glucose-6-phosphate dehydrogenase deficiency. J Pediatr 1995;127:804-6.

(20.) Kaplan M, Rubaltelli FF, Hammerman C, Vilei MT, Leiter C, Abramov A, et al. Conjugated bilirubin in neonates with glucose-6-phospate dehydrogenase deficiency. J Pediatr 1996;128(5 pt 1):695-7.

(21.) Edwards CQ. Anemia and the liver. Hepatobiliary manifestations of anemia. Clin Liver Dis 2002;6:891-907,viii.

(22.) Bhutani VK, Johnson LH, Keren R. Diagnosis and management of hyperbilirubinemia in the term neonate: for a safer first week. Pediatr Clin North Am 2004;51:843-61,vii.

(23.) American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation [published correction appears in Pediatrics 2004;114:1138]. Pediatrics 2004;114:297-316.

(24.) Valaes T. Fractionation of serum bilirubin conjugates in the exploration of the pathogenesis of significant neonatal bilirubinemia associated with glucose-6-phosphate dehydrogenase deficiency. J Pediatr 1997;130:678-9.

(25.) Kaplan M, Abramov A. Neonatal hyperbilirubinemia associated with glucose-6-phosphate dehydrogenase deficiency in Sephardic-Jewish neonates: incidence, severity, and the effect of phototherapy. Pediatrics 1992;90:401-5.

(26.) Slusher TM, Vreman HJ, McLaren DW, Lewison LJ, Brown AK, Stevenson DK. Glucose-6-phosphate dehydrogenase deficiency and carboxyhemoglobin concentrations associated with bilirubin-related morbidity and death in Nigerian infants. J Pediatr 1995;126:102-8.

(27.) Nair PA, Al Khusaiby SM. Kernicterus and G6PD deficiency--a case series from Oman. J Trop Pediatr 2003;49:74-7.

(28.) American Academy of Pediatrics Committee on Drugs. Transfer of drugs and chemicals into human milk. Pediatrics 2001;108:776-89.

(29.) Spolarics Z, Siddiqi M, Siegel JH, Garcia ZC, Stein DS, Ong H, et al. Increased incidence of sepsis and altered monocyte functions in severely injured type A-glucose-6-phosphate dehydrogenase-deficient African American trauma patients. Crit Care Med 2001;29:728-36.

(30.) CBBS e-Network Forums. Eligibility of prospective blood donors known to have G6PD deficiency. Accessed online July 20, 2005, at: http://www.cbbsweb.org/enf/ donor_g6pd.html.

(31.) Glucose-6-phosphate dehydrogenase deficiency. Accessed online July 20, 2005, at: http://www.thedoctorslounge. net/clinlounge/diseases/hematology/g6pd. htm.

(32.) Sharma SC, Sharma S, Gulati OP. Pycnogenol prevents haemolytic injury in G6PD deficient human erythrocytes. Phytother Res 2003;17:671-4.

JENNIFER E. FRANK, MAJ, MC, USA, is a residency staff member in the Department of Family Medicine at Martin Army Community Hospital in Fort Benning, Ga. She received her medical degree from Boston University School of Medicine and completed a family practice residency at Dewitt Army Community Hospital in Fort Belvoir, Va.

Address correspondence to Jennifer E. Frank, MAJ, MC, USA, Department of Family Medicine, Martin Army Community Hospital, 7950 Martin Loop, Fort Benning, GA 31905 (e-mail: Jennifer.Frank.@se.amedd.army.mil). Reprints are not available from the author.

COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group